Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Vijay Negi, PhD, Liat Goldberg, PhD, Yang Jo Chung, PhD, Masahiro Onozawa, MD, Peter D. Aplan, MD

Blood (2019) 134 (Supplement_1): 1346.

https://doi.org/10.1182/blood-2019-128675

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Terra Lasho, PhD, Alexander Tischer, PhD, Guadalupe Belen Antelo, MD, Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Giacomo Coltro, MD, Wilson I Gonsalves, MD, Ayalew Tefferi, MD, Abhishek A Mangaonkar, MBBS, Naseema Gangat, MBBS, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 1697.

https://doi.org/10.1182/blood-2019-128067

Published: 2019

Journal Articles

Comparison of Three Assays for Identification of IDH Mutations in AML

Sara Ribeiro, BSc, Dorte Wren, PhDFRCPath, Lisa Thompson, PhD MSc, FIBMS, Michael Hubank, PhD, David Taussig, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5195.

https://doi.org/10.1182/blood-2019-126494

Published: 2019

Journal Articles

A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia

Yu-Jun Dai, PhD, Fang Hu, Si-Yuan He, Xiao-Peng Tian, Hong-Hong Li, Ze-Yuan Qin, Siliang Chen, Yang Liang, PhD

Blood (2019) 134 (Supplement_1): 1426.

https://doi.org/10.1182/blood-2019-121657

Published: 2019

Journal Articles

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

Severine Cathelin, PhD, David Sharon, PhD, Amit Subedi, PhD, Dan Cojocari, PhD BSc, Darren C. Phillips, PhD, Joel D. Leverson, PhD, Kyle MacBeth, PhD, Brandon Nicolay, Rohini Narayanaswamy, Sebastien Ronseaux, Guowen Liu, PhD, Steven M Chan, MD PhD

Blood (2018) 132 (Supplement 1): 562.

https://doi.org/10.1182/blood-2018-99-119688

Published: 2018

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

Journal Articles

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Blood (2018) 132 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2018-99-118183

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 561.

https://doi.org/10.1182/blood-2018-99-110595

Published: 2018

Journal Articles

Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring

Sophie Broutin, PhD PharmD, Francois Lemonnier, MD PhD, Aurélie Dupuy, PhD, Julia Delahousse, Virginie Fataccioli, PhD, Vincent Ribrag, MD, Violaine Safar, MD, Laura Pelletier, Cyrielle Robe, Herve Tilly, MD, Anne Ségolène Cottereau, MD, Céline Bossard, MD, Laurence de Leval, MD, Marie-Helene Delfau, MD, Corinne Haioun, MD, Angelo Paci, PharmD, PhD, Philippe Gaulard, MD

Blood (2018) 132 (Supplement 1): 2898.

https://doi.org/10.1182/blood-2018-99-115893

Published: 2018

Journal Articles

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Tigran Ghazanchyan, MS, Dickran Kazandjian, MD, Donna Przepiorka, MD PhD, Kelly J. Norsworthy, MD, Emma Scott, PhD, Luis Santana-Quintero, PhD, Svetlana Petrovskaya, PhD, Yong Zhang, PhD, Amy Rosenberg, MD, Ashutosh Rao, PhD, Richard Pazdur, MD, Ann T. Farrell, MD, Julia A. Beaver, MD, Vahan Simonyan, PhD

Blood (2018) 132 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2018-99-116870

Published: 2018

Journal Articles

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Arko Das, MS, Krishna K Tiwari, BT, Vishwas Joseph, MS, Subrat Mohapatra, MS, Neelesh Lunkad, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3907.

https://doi.org/10.1182/blood.V130.Suppl_1.3907.3907

Published: 2017

Journal Articles

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Christophe Willekens, MD, Veronique Saada, Sophie Broutin, Julia Delahousse, Aline Renneville, MDPhD, Cynthia Petrovanu, Christophe Marzac, Jean-Baptiste Micol, MD PhD, Éric Solary, MD PhD, Florence Pasquier, MD PhD, Julien Lazarovici, MD, Vincent Ribrag, Claude Preudhomme, PharmD, PhD, Cyril Quivoron, Virginie Penard-Lacronique, PhD, Angelo Paci, Stephane de Botton, MD PhD

Blood (2017) 130 (Supplement 1): 1313.

https://doi.org/10.1182/blood.V130.Suppl_1.1313.1313

Published: 2017

Journal Articles

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Blood (2017) 130 (Supplement 1): 725.

https://doi.org/10.1182/blood.V130.Suppl_1.725.725

Published: 2017

Journal Articles

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Alice S. Mims, MD MSCR, Michael R. Savona, MD, Keith Pratz, MD, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Richard M. Stone, MD, Daniel A. Pollyea, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD PhD, Hartmut Döhner, MD, Gary J. Schiller, Ira V. Gupta, MD, Salah Nabhan, Vickie Zhang, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 726.

https://doi.org/10.1182/blood.V130.Suppl_1.726.726

Published: 2017

Journal Articles

A New Highly Sensitive Realtime PCR Assay with Faster Turnaround Time for Detecting IDH1 and IDH2 mutations in Acute Myeloid Leukemia (AML) Patients

Durga Prasad Dash, PhD, Laura Wise, MT(ASCP)CM, Jason Harb, PhD, Adam Knier, MB (ASCP), Muriel Boretsky, MB(ASCP)CM, Jennifer Simons, BA, Dina Berchanskiy, MS, Monika de Arruda Indig, PhD, Ajith M Joseph, PhD

Blood (2017) 130 (Supplement 1): 2681.

https://doi.org/10.1182/blood.V130.Suppl_1.2681.2681

Published: 2017

Journal Articles

Morphologic Assessment of Bone Marrow Samples in AML Patients Treated with Inhibitors to IDH1 and IDH2—a Single Center Experience

Jay Yang, MD, Ali M. Gabali, MD PhD

Blood (2017) 130 (Supplement 1): 5068.

https://doi.org/10.1182/blood.V130.Suppl_1.5068.5068

Published: 2017

Journal Articles

Utilization of a-Ketoglutarate for Synthesis of 2-Hydroxyglutarate Oncometabolite Promotes Catabolic Flexibility, Redox Perturbation and Mitochondrial Activity That Supports Chemoresistance in IDH1 Mutant Acute Myeloid Leukemia

Lucille Stuani, PhD, Christian Recher, MD PhD, Jean-Charles Portais, PhD, Jean-Emmanuel Sarry, PhD

Blood (2017) 130 (Supplement 1): 5080.

https://doi.org/10.1182/blood.V130.Suppl_1.5080.5080

Published: 2017

Journal Articles

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

Blood (2017) 130 (Supplement 1): 472.

https://doi.org/10.1182/blood.V130.Suppl_1.472.472

Published: 2017

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Comparison of Three Assays for Identification of IDH Mutations in AML

A Distinct Metabolic Signature in DNMT3A-Mutated Leukemia

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring

Developing a Genomics Model to Predict Failure of Isocitrate Dehydrogenase (IDH) Inhibitors for Treatment of Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Efficacy of 5-Azacitidine on IDH1/2 Acute Myeloid Leukemia/Myelodysplastic Syndromes and Correlation with 2-Hydroxyglutarate Production

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

A New Highly Sensitive Realtime PCR Assay with Faster Turnaround Time for Detecting IDH1 and IDH2 mutations in Acute Myeloid Leukemia (AML) Patients

Morphologic Assessment of Bone Marrow Samples in AML Patients Treated with Inhibitors to IDH1 and IDH2—a Single Center Experience

Utilization of a-Ketoglutarate for Synthesis of 2-Hydroxyglutarate Oncometabolite Promotes Catabolic Flexibility, Redox Perturbation and Mitochondrial Activity That Supports Chemoresistance in IDH1 Mutant Acute Myeloid Leukemia

Branched Chain Amino Acid Catabolism Restricts Alpha-Ketoglutarate Levels Resembling IDH mut -Driven DNA Hypermethylation in AML Stem Cells

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only